InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,914.71
(
2.23%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Bxofscidad

Send PM Follow Ignore
Followers 0
Posts 232
Boards Moderated 0
Alias Born 06/13/2010

Bxofscidad

Re: None

Monday, 09/26/2011 8:51:53 AM

Monday, September 26, 2011 8:51:53 AM

Post# of 80490
Please ponder this for a while


"Since the last data update from the trial was presented on December, 2010, all chronic-phase patients who achieved a MCyR remain in response with no signs of resistance"

I guess this sums up the efficafacy and durability of Ponatinib.


Bring on Gleevec


AS usual, JMHO

Barry
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up